چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Leptin is a 16 kDa hormone that is mainly expressed in adipose tissues (1). The major target of leptin is hypothalamus and it suppresses food intake and energy consumption, consequently diminishing adipose deposits and body weight (2, 3). The OB gene was isolated by Friedman in 1994 (4). Based on the suggestion of Roger Guillemin, Friedman named this new hormone 'leptin' from the Greek lepto meaning thin (5, 6). Since leptin discovery, numerous studies have been conducted on its physiological effects and its function in pathological conditions. Most of studies on leptin concentrated on its metabolic actions (7), receptors (8) and further broad functions such as immunity modulation (9) and memory processing (10). Considering such a vast range of functions, it is clear that patients with lack of leptin physiologically need pharmacological interventions. At this moment, we are in the twentieth year of leptin discovery. Finally, FDA approved a drug named Myalept (metreleptin for injection) on February 2014 to treat rare metabolic disease caused by leptin deficiency. Congenital generalized lipodystrophy is a disorder with partial lack of fat tissues (11). The trial for the safety and effectiveness of Myalept demonstrated decrease in HbA1c, fasting blood glucose, and triglycerides (11). Nevertheless, there are some limitations to the usage of Myalept in HIV-related lipodystrophy and some metabolic disorders (11). Moreover, it may increase the risk of lymphoma by producing anti-metreleptin antibodies neutralizing endogenous leptin. |
| نویسنده | نفر چندم مقاله |
|---|---|
| عطا محمودپور | اول |
| جواد محمودی | دوم |
| سعید صدیق اعتقاد | سوم |
| بابک صابرمعروف | چهارم |
| صمد اسلام جمال گلزاری | پنجم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| E-Leptin.pdf | 1398/09/05 | 222818 | دانلود |
